Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aclidinium Bromide Long-Term Safety and Efficacy in COPD
NCT01044459Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2009
- Primary completion
- Apr 2011
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of aclidinium in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by AstraZeneca. Primary endpoint: Change From Baseline in Morning Pre-dose (Trough) Forced Expiratory Volume in One Second at 52 weeks. Started Nov 2009; status: completed.
02
Drugs
aclidinium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01044459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01044459.